What does I.L.T.-PHARMA do?

I.L.T.-PHARMA is a plumber in Merksplas. Private Limited, started on 3 June 1996, 1 establishment.

What is the address of I.L.T.-PHARMA?

The registered office of I.L.T.-PHARMA is located at Schoondreef 18, 2330 Merksplas.

Is I.L.T.-PHARMA still active?

Yes. According to the CBE (30 October 2026) I.L.T.-PHARMA is active, legal situation “Normale toestand”, started on 3 June 1996.

Is I.L.T.-PHARMA registered on Peppol?

Yes, I.L.T.-PHARMA is registered on the Peppol network with ID 0208:0457997178.

What is the enterprise number of I.L.T.-PHARMA?

The enterprise number of I.L.T.-PHARMA is BE0457997178.

When was I.L.T.-PHARMA founded?

I.L.T.-PHARMA was founded on 3 June 1996.

Who are the directors of I.L.T.-PHARMA?

According to the 2025 annual accounts, the directors of I.L.T.-PHARMA are: Tom Lauwerysen, Kristel Dielis.

Is I.L.T.-PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 3 June 1996; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did I.L.T.-PHARMA make in 2025?

I.L.T.-PHARMA posted a profit after taxes of € 230,631 in financial year 2025.

What is the revenue of I.L.T.-PHARMA?

As a small company, I.L.T.-PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 537,094.

How many employees does I.L.T.-PHARMA have?

According to the 2025 annual accounts, I.L.T.-PHARMA has 0 full-time equivalents (FTE).

I.L.T.-PHARMA (Private Limited) - Merksplas

Dossier I.L.T.-PHARMA, printed on 30 October 2026 from databakkes.be/en/0457997178/i-l-t-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 63 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

I.L.T.-PHARMA from Merksplas, company number BE0457997178, closed financial year 2025 with a result of € 230,631 after tax. For that financial year I.L.T.-PHARMA recorded a gross margin of € 537,094 and equity of € 939,798. Compared with financial year 2024, the result moved from € 1,570 to € 230,631. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on December 16, 2025.

What it is worth Growing

€ 939,798

▲ 33% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 230,631

▲ € 229,062 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 666,692

▲ 148% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 623,298.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Vehicles and equipment

€ 1,731

▼ 43% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 960,092

▼ 47% vs 2024

€ 109,630 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 703

▼ 98% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 5,732

▲ 37% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 126,291 Gross margin 2022: € 126,291 First fiscal year in the series	€ 114,314 Gross margin 2023: € 114,314 ▼ 9% vs 2022 (€ 126,291) Unfavourable step	€ 125,636 Gross margin 2024: € 125,636 ▲ 10% vs 2023 (€ 114,314) Favourable step	€ 537,094 Gross margin 2025: € 537,094 ▲ € 411,459 vs 2024 (€ 125,636) Favourable step	▲ € 411,459
Profit after taxes	€ -41,202 Profit after taxes 2022: € -41,202 First fiscal year in the series	€ 8,132 Profit after taxes 2023: € 8,132 ▲ € 49,334 vs 2022 (€ -41,202) Favourable step	€ 1,570 Profit after taxes 2024: € 1,570 ▼ 81% vs 2023 (€ 8,132) Unfavourable step	€ 230,631 Profit after taxes 2025: € 230,631 ▲ € 229,062 vs 2024 (€ 1,570) Favourable step	▲ € 229,062
Equity	€ 1,224,464 Equity 2022: € 1,224,464 First fiscal year in the series	€ 1,232,597 Equity 2023: € 1,232,597 ▲ 1% vs 2022 (€ 1,224,464) Favourable step	€ 709,167 Equity 2024: € 709,167 ▼ 42% vs 2023 (€ 1,232,597) Unfavourable step	€ 939,798 Equity 2025: € 939,798 ▲ 33% vs 2024 (€ 709,167) Favourable step	▲ 33%
Total debts	€ 1,511,596 Total debts 2022: € 1,511,596 First fiscal year in the series	€ 1,486,416 Total debts 2023: € 1,486,416 ▼ 2% vs 2022 (€ 1,511,596) Favourable step	€ 2,822,238 Total debts 2024: € 2,822,238 ▲ 90% vs 2023 (€ 1,486,416) Unfavourable step	€ 1,841,071 Total debts 2025: € 1,841,071 ▼ 35% vs 2024 (€ 2,822,238) Favourable step	▼ 35%
Cash	€ 434,634 Cash 2022: € 434,634 First fiscal year in the series	€ 334,398 Cash 2023: € 334,398 ▼ 23% vs 2022 (€ 434,634) Unfavourable step	€ 268,960 Cash 2024: € 268,960 ▼ 20% vs 2023 (€ 334,398) Unfavourable step	€ 666,692 Cash 2025: € 666,692 ▲ 148% vs 2024 (€ 268,960) Favourable step	▲ 148%
Land & buildings	€ 1,781,385 Land & buildings 2022: € 1,781,385 First fiscal year in the series	€ 1,725,305 Land & buildings 2023: € 1,725,305 ▼ 3% vs 2022 (€ 1,781,385) Unchanged	€ 1,667,507 Land & buildings 2024: € 1,667,507 ▼ 3% vs 2023 (€ 1,725,305) Unchanged	€ 1,604,441 Land & buildings 2025: € 1,604,441 ▼ 4% vs 2024 (€ 1,667,507) Unchanged	▼ 4%
Retained profit	€ 907,964 Retained profit 2022: € 907,964 First fiscal year in the series	€ 916,097 Retained profit 2023: € 916,097 ▲ 1% vs 2022 (€ 907,964) Favourable step	€ 392,667 Retained profit 2024: € 392,667 ▼ 57% vs 2023 (€ 916,097) Unfavourable step	€ 623,298 Retained profit 2025: € 623,298 ▲ 59% vs 2024 (€ 392,667) Favourable step	▲ 59%
Dividend	€ 465,000 Dividend 2022: € 465,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 465,000) Unchanged	€ 525,000 Dividend 2024: € 525,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 525,000) Unchanged	▼ 100%
Bank debt	€ 1,027,105 Bank debt 2022: € 1,027,105 First fiscal year in the series	€ 987,283 Bank debt 2023: € 987,283 ▼ 4% vs 2022 (€ 1,027,105) Favourable step	€ 1,795,145 Bank debt 2024: € 1,795,145 ▲ 82% vs 2023 (€ 987,283) Unfavourable step	€ 960,092 Bank debt 2025: € 960,092 ▼ 47% vs 2024 (€ 1,795,145) Favourable step	▼ 47%
Balance sheet total	€ 2,736,060 Balance sheet total 2022: € 2,736,060 First fiscal year in the series	€ 2,719,013 Balance sheet total 2023: € 2,719,013 ▼ 1% vs 2022 (€ 2,736,060) Unchanged	€ 3,531,405 Balance sheet total 2024: € 3,531,405 ▲ 30% vs 2023 (€ 2,719,013) Unchanged	€ 2,780,869 Balance sheet total 2025: € 2,780,869 ▼ 21% vs 2024 (€ 3,531,405) Unchanged	▼ 21%

Key figures of I.L.T.-PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to I.L.T.-PHARMA?

What happened at I.L.T.-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Dec 16, 2025 New annual accounts for financial year 2025: profit of € 230,631 (▲ € 229,062 vs 2024). Source: NBB ↗
2007 Kristel Dielis became a director. NBB
1996 Tom Lauwerysen became a director. NBB
Jun 6, 1996 New establishment in Merksplas. KBO
Jun 3, 1996 Start of the company according to the CBE. KBO

In short

From € 41,202 loss in 2022 to € 230,631 profit in 2025.

Paid € 80,616 in corporate taxes since 2022.

Best year ever: 2025, with € 230,631 profit.

Paid out € 990,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Tom Lauwerysen Kristel Dielis

LT Projects

I.L.T.-PHARMA

Behind I.L.T.-PHARMA are Tom Lauwerysen and Kristel Dielis. The same people are also behind LT Projects.

Directors

According to the 2025 annual accounts

Tom Lauwerysen

Director

Also active at: LT Projects

since 1996

Kristel Dielis

Director

Also active at: LT Projects

since 2007

Establishments

Establishment units

Physical locations of this company

Registered office

Schoondreef 18

2330 Merksplas

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

LT Projects same network

€ 235,735 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0457.997.178

VAT number

BE 0457.997.178

Registered office

Schoondreef 18, 2330 Merksplas

Names & denominations

I.L.T.-PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

3 June 1996

Peppol

Active · Active since 17 Feb 2025

Activities · NACE

Sanitaire werkzaamheden

Overig loodgieterswerk

Activiteiten van holdings

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Verhuur en lease van andere machines en werktuigen en andere materiële goederen

Overige adviesbureaus op het gebied van bedrijfsvoering en beheer

Managementactiviteiten van holdings

Verhuur van overige machines en werktuigen, n.e.g.

View on CBE Public ↗ Annual accounts (NBB) ↗

I.L.T.-PHARMA

Warning lights

Financials

What happened to I.L.T.-PHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions